Zealand headed for potential blockbuster market
Danish biotech company Zealand Pharma could have a new blockbuster on its hands, assuming the recently initiated phase II study with candidate drug danegaptid yields strong data, says an analyst. CEO David Solomon believes the company is becoming a “significant player”.
by Stefan Singh Kailay
With last week’s announcement about the initiation of a new phase II study with heart medicine danegaptid, Danish biotech outfit Zealand Pharma could be headed for a blockbuster market. But the company still has to prove some things, according to Thomas Bowers, pharma analyst for Danske Bank.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Zealand initiates own phase II study
For abonnenter
Zealand: An unlucky year for us, but…
For abonnenter
